FDA Approves RHA Redensity Eye for Infraorbital Volume Deficiencies
FDA approves RHA Redensity Eye for correction of moderate to severe tissue volume deficiencies in the infraorbital region in adults ages 22 and older.
FDA approves RHA Redensity Eye for correction of moderate to severe tissue volume deficiencies in the infraorbital region in adults ages 22 and older.
Operating with a 16W diode, the platform expands full-body skin revitalization settings across mJOULE and JOULE X systems.